BioPharmSignal logoBioPharmSignal

Biotech News

Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia

BioNano Genomics (BNGO)BioNano GenomicsCompany update

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) detected genomic abnormalities in 97.8% of T-cell acute lymphoblastic leukemia (T-ALL) cases — nearly

Related news

BNGOBioNano Genomics2026-06-11 12:00 EST

Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders

BNGOBioNano Genomics2026-05-05 12:00 EST

Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025

View all latest news

BioNano Genomics

Genome Analysis Platform Bionano provides optical genome mapping systems and software for identifying structural variants and interpreting genomic data. Saphyr and OGM The Saphyr platform images ultra-high-molecular-weight DNA to detect large genomic changes that can be missed by conventional cytogenetics or short-read sequencing. VIA...

Recent company news

BNGOBioNano Genomics2026-08-24 12:00 EST

Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

BNGOBioNano Genomics2026-08-10 20:05 EST

Bionano Reports Second Quarter 2026 Results and Provides a Business Update

BNGOBioNano Genomics2026-07-27 20:05 EST

Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026

BNGOBioNano Genomics2026-06-24 12:30 EST

Bionano Announces Hiring of Chief Scientific Officer

BNGOBioNano Genomics2026-06-18 12:00 EST

Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption

Stock data

Close
1.20 USD
Market cap
14.46M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States